Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease.
暂无分享,去创建一个
[1] J. Oates,et al. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. , 1983, The Journal of clinical investigation.
[2] J. Oates,et al. Metabolic disposition of prostacyclin in humans. , 1983, The Journal of pharmacology and experimental therapeutics.
[3] G. FitzGerald,et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. , 1983, The Journal of clinical investigation.
[4] E. Granström,et al. Profiles of prostaglandin metabolites in the human circulation. Identification of late-appearing, long-lived products. , 1982, Biochimica et biophysica acta.
[5] C. Patrono,et al. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. , 1982, The Journal of clinical investigation.
[6] G. Galanti,et al. Reduced prostacyclin production in patients with different manifestations of ischemic heart disease. , 1982, The American journal of cardiology.
[7] C. Dollery,et al. Prostacyclin is not a circulating hormone in man. , 1982, Prostaglandins.
[8] W. Siess,et al. Very low levels of 6-keto-prostaglandin F1 alpha in human plasma. , 1982, The Journal of laboratory and clinical medicine.
[9] J. Oates,et al. Estimated rate of prostacyclin secretion into the circulation of normal man. , 1981, The Journal of clinical investigation.
[10] C. Patrono,et al. Pulmonary formation of prostacyclin in man. , 1981, Prostaglandins.
[11] C. Stoddard,et al. Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin. , 1981, The New England journal of medicine.
[12] M. Claeys,et al. Quantitative determination of 6-Oxo-PGF1 alpha in biological fluids by gas chromatography mass spectrometry. , 1980, Biomedical mass spectrometry.
[13] J. Mcgiff,et al. Metabolism of prostacyclin by 9-hydroxyprostaglandin dehydrogenase in human platelets. Formation of a potent inhibitor of platelet aggregation and enzyme purification. , 1980, The Journal of biological chemistry.
[14] V. Kakkar,et al. β-Thromboglobulin - a Specific Marker of In-Vivo Platelet Release Reaction , 1980, Thrombosis and Haemostasis.
[15] G. Friesinger,et al. Platelet Aggregates in Ischemic Heart Disease , 1980, Thrombosis and Haemostasis.
[16] J. Mcgiff,et al. 6‐Keto PGExi A Possible Metabolite of Prostacyclin Having Platelet Antiaggregatory Effects , 1980, Hypertension.
[17] C. Patrono,et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. , 1980, Thrombosis research.
[18] C. Patrono,et al. Characterization of furosemide-induced activation of the renal prostaglandin system. , 1979, European journal of pharmacology.
[19] C. Dollery,et al. PRODUCTION OF 6-OXO-PGF1α BY HUMAN LUNG IN VIVO , 1979, The Lancet.
[20] H. Sinzinger,et al. PROSTACYCLIN GENERATION IN ATHEROSCLEROTIC ARTERIES , 1979, The Lancet.
[21] G. Fitzgerald,et al. A double blind placebo controlled crossover study of prostacyclin in man. , 1979, Life sciences.
[22] J. Vane,et al. Prostacyclin is a circulating hormone , 1978, Nature.
[23] R. Gryglewski,et al. Generation of prostacyclin by lungs in vivo and its release into the arterial circulation , 1978, Nature.
[24] J. Vane,et al. Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. , 1978, British medical bulletin.
[25] J. Vane,et al. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. , 1976, Prostaglandins.
[26] J. Vane,et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation , 1976, Nature.
[27] J. Mustard,et al. Factors influencing platelet function: adhesion, release, and aggregation. , 1970, Pharmacological reviews.
[28] L. Harker,et al. Thrombokinetics in man. , 1969, The Journal of clinical investigation.
[29] H. W. Seyberth,et al. Urinary excretion rate of 6-keto-prostaglandin F1 alpha as an index of circulating prostacyclin. , 1983, Advances in prostaglandin, thromboxane, and leukotriene research.
[30] C. Patrono,et al. Evidence for a renal origin of urinary thromboxane B2 in health and disease. , 1983, Advances in prostaglandin, thromboxane, and leukotriene research.
[31] C. Patrono,et al. Evidence for a direct stimulatory effect of prostacyclin on renin release in man. , 1982, The Journal of clinical investigation.
[32] R. Branch,et al. 6-Keto-prostaglandin E1 is more potent than prostaglandin I2 as a renal vasodilator and renin secretagogue. , 1981, The Journal of pharmacology and experimental therapeutics.
[33] E. Christ-Hazelhof,et al. Determination of Nanogram Quantities of Eicosanoids as their Pentafluorobenzyl Derivatives by Gas Chromatography with Electron-Capture Detection , 1980 .
[34] B. Samuelsson. THE ROLE OF PROSTAGLANDIN ENDOPEROXIDES AND THROMBOXANES AS BIOREGULATORS , 1977 .